Huafeng Kang

4.0k total citations · 1 hit paper
132 papers, 2.9k citations indexed

About

Huafeng Kang is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Huafeng Kang has authored 132 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Molecular Biology, 52 papers in Oncology and 38 papers in Cancer Research. Recurrent topics in Huafeng Kang's work include Breast Cancer Treatment Studies (14 papers), Cancer-related molecular mechanisms research (12 papers) and Flavonoids in Medical Research (11 papers). Huafeng Kang is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), Cancer-related molecular mechanisms research (12 papers) and Flavonoids in Medical Research (11 papers). Huafeng Kang collaborates with scholars based in China, United States and Germany. Huafeng Kang's co-authors include Zhijun Dai, Xi-Jing Wang, Shuai Lin, Xiaobin Ma, Yi Zheng, Yujiao Deng, Haitao Guan, Linghui Zhou, Zhen Zhai and Na Li and has published in prestigious journals such as Advanced Functional Materials, Journal of Agricultural and Food Chemistry and Scientific Reports.

In The Last Decade

Huafeng Kang

121 papers receiving 2.8k citations

Hit Papers

Global burden of breast cancer and attributable risk fact... 2019 2026 2021 2023 2019 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017
    2019 267 citations Na Li, Yujiao Deng et al. profile →

Peers

Huafeng Kang
Graham P. Pidgeon Ireland
Da‐Tian Bau Taiwan
Marco A. De Velasco Japan
Susan Goodin United States
Ashish Saxena United States
Howard H. Bailey United States
Imad Shureiqi United States
Karol Kajo Slovakia
Rong Hu China
Manuel González-Barón Spain
Graham P. Pidgeon Ireland
Huafeng Kang
Citations per year, relative to Huafeng Kang Huafeng Kang (= 1×) peers Graham P. Pidgeon

Countries citing papers authored by Huafeng Kang

Since Specialization
Citations

This map shows the geographic impact of Huafeng Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huafeng Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huafeng Kang more than expected).

Fields of papers citing papers by Huafeng Kang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huafeng Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huafeng Kang. The network helps show where Huafeng Kang may publish in the future.

Co-authorship network of co-authors of Huafeng Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Huafeng Kang. A scholar is included among the top collaborators of Huafeng Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huafeng Kang. Huafeng Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lyu, Lijuan, Ming Yi, Jihua Chen, et al.. (2025). Bispecific Antibody Targeting VEGF/TGF‐β Synergizes with Local Radiotherapy: Turning Tumors from Cold to Inflamed and Amplifying Abscopal Effects. Advanced Science. 12(30). e01819–e01819. 1 indexed citations
2.
Zhou, Yuqing, Huafeng Kang, Xiaoguang Zhang, et al.. (2025). Combining immunomagnetic beads and the phage lysin LysGH15 for fluorescence detection of Staphylococcus aureus. Analytica Chimica Acta. 1368. 344300–344300.
3.
4.
Liu, Dandan, Xuyan Zhao, Xueting Ren, et al.. (2024). Can neoadjuvant systemic therapy provide additional benefits for T1 HER2+ breast cancer patients: a subgroup analysis based on different high-risk signatures. Clinical & Translational Oncology. 26(9). 2323–2338.
5.
Xu, Peng, Zhangjian Zhou, Shuai Lin, et al.. (2024). Favorable outcome of neoadjuvant endocrine treatment than surgery‐first in female HR‐positive/HER2‐negative breast cancer patients—A NCDB analysis (2010–2016). Cancer Medicine. 13(11). e7244–e7244. 1 indexed citations
6.
Liu, Dandan, Qian Hao, Xueting Ren, et al.. (2024). Impact of response to neoadjuvant chemotherapy on surgical modality in patients with T1-2N0-1M0 triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology. 150(8). 378–378.
7.
8.
Ren, Xueting, et al.. (2023). Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer. Frontiers in Immunology. 14. 1145552–1145552. 13 indexed citations
9.
Lin, Shuai, Xiaobin Ma, Peng Xu, et al.. (2022). Marsdenia tenacissima Extract Induces Autophagy and Apoptosis of Hepatocellular Cells via MIF/mToR Signaling. Evidence-based Complementary and Alternative Medicine. 2022. 1–10. 8 indexed citations
10.
Zheng, Yi, Si Yang, Yujiao Deng, et al.. (2022). BMPR1B Polymorphisms (rs1434536 and rs1970801) are Associated With Breast Cancer Susceptibility in Northwest Chinese Han Females: A Case-Control Study. Clinical Breast Cancer. 22(5). e641–e646. 4 indexed citations
11.
Ren, Xueting, Nan Wang, Dandan Liu, et al.. (2022). Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer. Cancer Medicine. 11(20). 3886–3901. 16 indexed citations
12.
Zhou, Zhangjian, Shuai Lin, Xin Zhang, et al.. (2022). Prognostic effect of radiotherapy in breast cancer patients underwent immediate reconstruction after mastectomy. Frontiers in Oncology. 12. 1010088–1010088. 4 indexed citations
13.
Wu, Jian, Xuan Wang, Nan Wang, et al.. (2021). Identification of novel antioxidant gene signature to predict the prognosis of patients with gastric cancer. World Journal of Surgical Oncology. 19(1). 219–219. 16 indexed citations
14.
Ma, Xiaobin, Chengxue Dang, Weili Min, et al.. (2019). Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression. Breast Cancer Research and Treatment. 176(1). 109–117. 15 indexed citations
15.
Zhou, Linghui, Shan‐Shan Dong, Yujiao Deng, et al.. (2019). GOLGA7 rs11337, a Polymorphism at the MicroRNA Binding Site, Is Associated with Glioma Prognosis. Molecular Therapy — Nucleic Acids. 18. 56–65. 13 indexed citations
16.
Song, Lingqin, Di Liu, Yang Zhao, et al.. (2018). Sinomenine reduces growth and metastasis of breast cancer cells and improves the survival of tumor-bearing mice through suppressing the SHh pathway. Biomedicine & Pharmacotherapy. 98. 687–693. 26 indexed citations
17.
Wang, Xiaolong, Lei Sun, Xi-Jing Wang, et al.. (2017). Acidified bile acids enhance tumor progression and telomerase activity of gastric cancer in mice dependent on c‐Myc expression. Cancer Medicine. 6(4). 788–797. 32 indexed citations
18.
Ma, Xiaobin, Xi-Jing Wang, Meng Wang, et al.. (2016). Impact of the PARP1 rs1136410 and rs3219145 polymorphisms on susceptibility and clinicopathologic features of breast cancer in a Chinese population. Translational Cancer Research. 5(5). 520–528. 1 indexed citations
19.
Dai, Zhijun, Xi-Jing Wang, Yang Zhao, et al.. (2014). Effects of Interleukin-10 Polymorphisms (rs1800896, rs1800871, and rs1800872) on Breast Cancer Risk: Evidence from an Updated Meta-Analysis. Genetic Testing and Molecular Biomarkers. 18(6). 439–445. 17 indexed citations
20.
Dai, Zhijun, et al.. (2007). [HER-2 expression in local advanced breast cancer and the efficacy of neoadjuvant chemotherapy regimens].. PubMed. 27(9). 1397–9. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Graham P. Pidgeon Breakdown of academic impact, for papers by Da‐Tian Bau Breakdown of academic impact, for papers by Marco A. De Velasco Breakdown of academic impact, for papers by Susan Goodin Breakdown of academic impact, for papers by Ashish Saxena Breakdown of academic impact, for papers by Howard H. Bailey Breakdown of academic impact, for papers by Imad Shureiqi Breakdown of academic impact, for papers by Karol Kajo Breakdown of academic impact, for papers by Rong Hu Breakdown of academic impact, for papers by Manuel González-Barón
Rankless by CCL
2026